Critically IllPROMIZINGNCT02447692
Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The PROMIZING Study
A study testing PSV ventilation strategy and PAV+ ventilation strategy in people with Critically Ill and Acute Respiratory Failure, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's at 22 sites in 7 countries.
Trial summary
For adult patients with acute respiratory failure requiring invasive mechanical ventilation, does a ventilation strategy using proportional assist ventilation with load-adjustable gain factors (PAV+) result in a shorter duration of time spent on mechanical ventilation than a ventilation strategy using pressure support… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Critically Ill, Acute Respiratory Failure
- What is being tested?
- PSV ventilation strategy and PAV+ ventilation strategy
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 575 participants
- Where
- 22 sitesin 7 countries
- Study dates
- 14 Sep 2016to 16 Jul 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
A staged enrolment process will be used to identify patients eligible to be enrolled and randomized in the study. At each stage of the enrolment process, a patient must meet inclusion criteria and not meet exclusion criteria in order to pass. To progress to the next stage, patients must continue to pass criteria from the prior stages. After enrolment, there are also specific tests to perform (with pass/fail criteria) to determine eligibility to be randomized.
- SCREENING INCLUSION CRITERIA:
- A1. Age 18 years or older
- A2. Intubated and receiving any mode of invasive mechanical ventilation ≥ 24 hours
- SCREENING EXCLUSION CRITERIA:
- A3. Anticipating withdrawal of life support and/or shift to palliation as the goal of care
- A4. Severe central neurologic disorder (eg. Hemorrhage, stroke, tumour) causing elevated intracranial pressure, or impaired control of breathing, or requiring specific ventilator adjustments (i.e. To attain specific CO2 target) or requiring neurosurgical intervention
- A5. Known or suspected severe or progressive neuromuscular disorder likely to result in prolonged or chronic ventilator dependence (eg. Guillain-Barré syndrome, Myasthenia Gravis, ALS, MS, high spinal cord injury, kyphoscoliosis or other restrictive disorder) (Note that obesity hypoventilation syndrome that may be managed with nocturnal non-invasive ventilation is NOT an exclusion under A5)
- A6. Severe COPD: Baseline daytime hypercapnia (pCO2> 50 mmHg) OR GOLD 4 airflow limitation (FEV1<30% predicted) OR MRC class 4 symptoms ("I am too breathless to leave the house" OR "I am breathless when dressing")
- A7. Broncho-pleural fistula
- A8. Tracheostomy present at ICU admission for the purpose of chronic or prolonged mechanical ventilation (>21 days). (Note that a patient who was endotracheally intubated for acute respiratory failure and received a tracheostomy during their ICU admission, prior to enrolment, is not excluded under A8).
- A9. Current enrolment in a confounding study, as assessed by the steering committee
- A10. Previous randomization in the PROMIZING Study
- A11. Severe, end-stage, irreversible respiratory or cardiac disease (e.g. interstitial lung disease, pulmonary fibrosis, cardiomyopathy, valvulopathy) likely to result in prolonged or chronic ventilator dependence /unlikely to wean from mechanical ventilation [Note: patients who are candidates for intervention to treat the underlying respiratory/cardiac disease (e.g. lung transplant, heart transplant, cardiac surgery) may be re-evaluated once intervention is complete and they no longer meet criteria A11.]
- ENROLMENT INCLUSION CRITERIA:
- B1. Ability or potential ability to trigger ventilator breaths (i.e. not receiving neuromuscular blockade).
- B2. On Assist/Control volume-cycled ventilation: Technically satisfactory plateau pressure ≤ 30 cm H2O (see Operations Manual) OR On Assist/Control pressure-controlled ventilation or similar mode: Pressure control plus PEEP ≤ 30 cm H2O OR On Pressure Support ventilation: Pressure support plus PEEP ≤ 30 cm H2O OR On Proportional Assist ventilation: PAV gain <85%
- B3. PaO2 ≥ 60 mmHg or SpO2 ≥ 90% on FiO2 ≤ 0.60 and PEEP ≤ 15 cm H2O
- B4. Metabolic disorders corrected: pH ≥7.32
- B5. Stable hemodynamic status: stable or decreasing doses of vasopressors for ≥6 hours
- B6. Anticipate ongoing need for ventilation >24 hours
- ENROLMENT EXCLUSION CRITERIA:
- B7. Extubated
- B8. Died
- B9. Patient has met enrolment inclusion criteria B1-B5 AND has tolerated pressure support of 0-20 cm H2O or proportional assist ventilation of 0-85% for ≥24 consecutive hours (including time on CPAP, t-piece, or tracheostomy mask). (Note (1): that it is acceptable to include a patient who has been tried on pressure support or proportional assist ventilation but has required pressures >20 cmH2O or assistance >85% or has required return to A/C ventilation within the 24 hour time window; Note (2): B9 does not apply to patients on ECMO.)
- B10. Patient transferred to a non-participating centre
- ENROLMENT DEFERRAL CRITERIA:
- B11. Plan to extubate/discontinue mechanical ventilation within <24 hours (Reassess within 24 hours)
- B12. Patient currently on ECMO (Reassess patient once off ECMO)
- C9: Plan for surgery or complex procedure that will require full ventilation to be done prior to attempting extubation (e.g. Procedure requiring neuromuscular blockade and/or heavy sedation, such that patient would be apneic, or not be able to trigger ventilator) (Reassess after surgery/procedure complete)
- PRESSURE SUPPORT TRIAL INCLUSION CRITEIRA:
- C2. Upon review of Screening and Enrolment criteria (A and B), the patient still passes.
- C3. Treating physician has provided verbal consent to proceed with standardized tests and randomization if eligibility criteria are met.
- PRESSURE SUPPORT TRIAL DEFERRAL CRITERIA:
- C6. High dose vasopressor requirements (i.e. epinephrine or norepinephrine >0.5 ug/kg/min or equivalent) OR patient requiring an increase in dose of vasopressor within 6 hrs
- C7. Active cardiac ischemia (dynamic ST changes on monitor or ECG within 6 hours)
- C8. Unstable arrhythmias (HR>140 or <50) with clinical signs of low cardiac output or or SBP<80 mmHg
- C10. Receiving a "strict lung protective" ventilation strategy for ARDS (eg. Order on chart to keep Vt ≤6 mL/kg PBW)
- PRESSURE SUPPORT TRIAL EXCLUSION CRITERIA:
- C12. Treating physician has declined consent
- WEANING CRITERIA:
- D1. SpO2≥ 90% on FiO2 ≤0.40 and PEEP ≤8 cmH2O
- D2. pH ≥7.32
- D3. Vasopressor requirements no higher than norepinephrine 0.1 ug/kg/min or equivalent.
In the final stage (E), patients will be considered eligible for randomization if the following criteria are met.
- RANDOMIZATION INCLUSION CRITERIA:
- C1. Patient/SDM has provided consent OR Plan to obtain deferred consent as Patient incapable and no SDM available to provide consent within the randomization window
- E1. Upon review of Criteria A, B, and C, the patient still passes and the patient has passed the PST.
- E2. Does not meet Weaning Criteria OR Fails the ZERO CPAP Trial OR Fails the SBT
- RANDOMIZATION EXCLUSION CRITERIA:
- B9. Patient has met enrolment inclusion criteria B1-B5 AND has tolerated pressure support of 0-20 cm H2O or proportional assist ventilation of 0-85% ≥24 consecutive hours (including time on CPAP, t-piece, or tracheostomy mask). Note (1): It is acceptable to include a patient who has been tried on pressure support or proportional assist ventilation but has required pressures >20 cmH2O or assistance >85% or has required return to A/C ventilation within the 24 hour time window; Note (2): B9 does not apply to patients while on ECMO
- C4. Patient/SDM has declined consent
- C5. Patient incapable and no SDM available to provide consent (not applicable if plan to obtain deferred consent)
- E3. Passed SBT on t-piece, FiO2 0.40 for 30-120 minutes
- E4. Approval withdrawn (by physician or patient/SDM)
Trial locations and contacts
22 sites in 7 countries.
22 sites in 7 countries
Canada11 sites
Kingston General Hospital
Kingston, Ontario
London Health Sciences Centre - University Hospital
London, Ontario, N6A 5A5
Victoria Hospital
London, Ontario
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, GC6R+GW
Royal Victoria Hospital
Montreal, Quebec
Institut Universitaire de cardiologie et de pneumologie de Quebec
Québec, Quebec
Sunnybrook Hospital - Health Sciences Centre
Toronto, Ontario, M4N 3M5
North York General Hospital
Toronto, Ontario
St. Michael's Hospital
Toronto, Ontario
UHN- Toronto General Hospital
Toronto, Ontario
UHN- Toronto Western Hospital
Toronto, Ontario
France5 sites
Centre Hospitalier Universitaire (CHU) de Angers
Angers
Centre Hospitalier Intercommunal de Créteil
Créteil, QFW8+H5
Hôpital Henri Mondor (Assistance Publique-Hôpitaux de Paris)
Créteil
Hôpital Universitaire Pitié-Salpêtrière
Paris
Centre Hospitalier Universitaire (CHU) de Rouen
Rouen
Italy2 sites
University Hospital of Ferrara
Ferrara
San Giovanni Battista University Hospital
Turin
Argentina1 site
El Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"
Buenos Aires, C1430EFA
About this study
For adult patients with acute respiratory failure requiring invasive mechanical ventilation, does a ventilation strategy using proportional assist ventilation with load-adjustable gain factors (PAV+) result in a shorter duration of time spent on mechanical ventilation than a ventilation strategy using pressure support ventilation (PSV)?
Read the detailed description
Patients with acute respiratory failure require mechanical ventilation to help them breathe until they recover from their acute illness. Although mechanical ventilation is necessary to sustain life in such situations, it can induce weakness of the respiratory muscles which may lead to prolonged dependence on the ventilator. Prolonged dependence on mechanical ventilation is associated with increased mortality, morbidity and costs to the healthcare system. Thus, a main goal of assisted mechanical ventilation is to reduce the patient's respiratory distress while maintaining some respiratory muscle activity. To attain this goal, the amount of ventilator assistance should theoretically be adjusted to target normal or reasonable levels of respiratory effort.
Modes of Mechanical Ventilation:
Proportional assist ventilation with load-adjustable gain factors (PAV+) is a mode of mechanical ventilation which delivers assistance to breathe in proportion to the patient's effort. The proportional assistance, called the gain, can be adjusted by the clinician to maintain the patient's respiratory effort or workload within a reasonable range. This is the only mode of ventilation which allows for measurement and targeting of a specific range of respiratory muscle activity by the patient.
Pressure support ventilation (PSV) is a mode of ventilation which is considered the current standard of care for assisting breathing of patients during the recovery phase of acute respiratory failure. Several studies have shown short term advantages of PAV over PSV, including improved patient-ventilator synchronization, improved adaptability to changes in patient effort, and improved sleep quality.
Goal of this Randomized Controlled Trial:
To demonstrate that for patients with acute respiratory failure, ventilation with PAV+, being more physiological, will result in a shorter duration of time spent on mechanical ventilation than ventilation with PSV.
- Conditions
- Critically Ill, Acute Respiratory Failure
- Being tested
- PSV ventilation strategy, PAV+ ventilation strategy
- Keywords
- Proportional Assist Ventilation, Pressure Support Ventilation, Weaning
- Medical subject headings
- Critical Illness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PSV ventilation strategyOther
An algorithm for adjusting the level of pressure support according to usual clinical parameters; patients not tolerating PSV will be switched to Assist/Control mode according to predefined criteria
PAV+ ventilation strategyOther
An algorithm for adjusting the level of support (gain) to maintain a predefined range of respiratory muscle pressure; patients not tolerating PAV+ (Puritan Bennett™ 840 or 980 ventilator) will be switched to Assist/Control mode according to predefined criteria
| Study group | Role | What they receive |
|---|---|---|
| PSV ventilation strategy | Active comparator | The control is the standard of care PSV ventilation strategy, designed to adjust the level of support according to usual clinical parameters. Receives: Other: PSV ventilation strategy |
| PAV+ ventilation strategy | Active comparator | The intervention is a PAV+ ventilation strategy, designed to adjust the level of support (gain) to target a predefined range of respiratory muscle pressure. Receives: Other: PAV+ ventilation strategy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time from randomization to successful liberation from invasive mechanical ventilation.
"Successful liberation" is defined as removal of the endotracheal tube AND remaining alive with no need for reintubation/reinstitution of invasive mechanical ventilation for 7 days post extubation, or until successful ICU discharge, or until live hospital discharge, whichever comes first.
Measured: up to 90 days
Secondary outcomes (9)
Ventilator-free days at 14, 21 and 28 days post randomization
"Ventilator-free days" (VFDs) are defined as the number of days alive and free of INVASIVE ventilation post SUCCESSFUL EXTUBATION or post successful termination of invasive mechanical ventilation (MV) from time of randomization to day 21 post randomization. "Successful extubation" is defined as removal of the endotracheal tube AND remaining alive with no need for reintubation/reinstitution of invasive mechanical ventilation for 7 days post extubation, or until successful ICU discharge, or until live hospital discharge, whichever comes first.
Measured: 14, 21 and 28 days post randomization
Time from randomization to live ICU discharge (up to day 90)
Patients will remain in the study and will continue on the assigned ventilation strategy until: successful extubation, successful ICU discharge, live hospital discharge, death, or 90 days post randomization, whichever comes first.
Measured: up to 90 days
Time from randomization to live hospital discharge (up to day 90)
Patients will remain in the study and will continue on the assigned ventilation strategy until: successful extubation, successful ICU discharge, live hospital discharge, death, or 90 days post randomization, whichever comes first.
Measured: up to 90 days
Mortality
Measured as time to death, ICU mortality; hospital mortality; 21, 28, and 90 day mortality
Measured: up to 90 days
Weaning Progress
Measured as time from randomization to: first SBT; first successful SBT; first extubation
Measured: up to 90 days
Weaning Difficulties
Measured as the number of patients failing first SBT or first extubation attempt and requiring up to 7 days to extubate (difficult weaning group/group 2); failing first SBT or first extubation attempt and requiring more than 7 days to extubate (prolonged weaning group/group 3)
Measured: 90 days
Weaning Complications
Measured as the number of patients: requiring non-invasive ventilation post-extubation; ventilated more than 7 days post randomization, ventilated more than 21 days from time of intubation (prolonged MV group); receiving tracheostomy post-randomization, requiring re-intubation (up to 7d after planned extubation)
Measured: 90 days
Tolerance of modes
Measured as number of patients ever requiring A/C mode post randomization; number of patient-days requiring A/C mode post randomization
Measured: 90 days
Serious Adverse Events
Incidence of reported serious adverse events
Measured: 90 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 May 2015 (estimated)
- Study start14 Sep 2016
- Primary completion16 Jul 2024
- Study completion16 Jul 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Critically IllStudies of the same condition, open and under way.
- More trials run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 575 participants (actual)
Sponsor and investigators
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Sponsor type
- University, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR), Medtronic, Canadian Critical Care Trials Group
- Responsible party
- Sponsor
- Investigators
- Karen J Bosma, Principal investigator, London Health Sciences Centre, London, Ontario, CanadaLaurent Brochard, Principal investigator, St. Michael's Hospital, Toronto, Ontario, Canada
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02447692
- Sponsor's protocol ID
- IPR-327433, ISR-2014-10481
- Acronym
- PROMIZING
- Status last verified
- Aug 2024
- First submitted
- 8 May 2015
- Last updated
- 22 May 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data will be collected electronically and stored at the Clinical Coordinating Center at the Applied Health Research Centre (AHRC). A de-identified database of all data may be made available for use 3 years after the primary publication upon request and review of the statistical analysis plan by the PROMIZING steering committee.
Publications
Bosma KJ, Burns KEA, Martin CM, Skrobik Y, Mancebo Cortes J, Mulligan S, Lafreniere-Roula M, Thorpe KE, Suarez Montero JC, Moran Chorro I, Rodriguez-Farre N, Butler R, Bentall T, Beduneau G, Enguerrand P, Santos M, Piraino T, Spadaro S, Montanaro F, Basmaji J, Campbell E, Mercat A, Beloncle FM, Carteaux G, Maraffi T, Charbonney E, Lecronier M, Dres M, Arabi YM, Amaral ACK, Marinoff N, Adhikari NKJ, Geagea A, Shin P, Vaporidi K, Kondili E, Shahin J, Campisi J, Rodriguez PO, Setten M, Goligher EC, Ferguson ND, Fanelli V, Ferreyra G, Lellouche F, Sibley S, Brochard L; PROMIZING Study Investigators, the Canadian Critical Care Trials Group, and the REVA Network. Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation. N Engl J Med. 2025 Sep 18;393(11):1088-1103. doi: 10.1056/NEJMoa2505708. Epub 2025 Jun 13.
PubMed 40513024Bosma KJ, Lafreniere-Roula M, Jiang A, Heath A, Ouyang Y, Wade K, Hu P, Burns KEA, Martin CM, Skrobik Y, Mulligan S, Thorpe KE, Brochard L; members of the Canadian Critical Care Trials Group and the REVA Network. Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation (the PROMIZING study): update to the statistical analysis plan for a randomized controlled trial. Trials. 2024 Dec 30;25(1):855. doi: 10.1186/s13063-024-08669-7.
PubMed 39736673Bosma KJ, Martin CM, Burns KEA, Mancebo Cortes J, Suarez Montero JC, Skrobik Y, Thorpe KE, Amaral ACK, Arabi Y, Basmaji J, Beduneau G, Beloncle F, Carteaux G, Charbonney E, Demoule A, Dres M, Fanelli V, Geagea A, Goligher E, Lellouche F, Maraffi T, Mercat A, Rodriguez PO, Shahin J, Sibley S, Spadaro S, Vaporidi K, Wilcox ME, Brochard L; Canadian Critical Care Trials Group and; REVA Network. Study protocol for a randomized controlled trial of Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: the PROMIZING study. Trials. 2023 Mar 27;24(1):232. doi: 10.1186/s13063-023-07163-w.
PubMed 36973743
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The PROMIZING Study
- ClinicalTrials.gov ID
- NCT02447692
- Acronym / sponsor ID
- PROMIZING / IPR-327433, ISR-2014-10481
- Conditions
- Critically Ill, Acute Respiratory Failure
- Keywords
- Proportional Assist Ventilation, Pressure Support Ventilation, Weaning
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 575 participants (actual)
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sUniversity, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR), Medtronic, Canadian Critical Care Trials Group
- Study start
- 14 Sep 2016 (actual)
- Primary completion
- 16 Jul 2024 (actual)
- Study completion
- 16 Jul 2024 (actual)
- First posted
- 19 May 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
For adult patients with acute respiratory failure requiring invasive mechanical ventilation, does a ventilation strategy using proportional assist ventilation with load-adjustable gain factors (PAV+) result in a shorter duration of time spent on mechanical ventilation than a ventilation strategy using pressure support ventilation (PSV)?
Detailed description
Patients with acute respiratory failure require mechanical ventilation to help them breathe until they recover from their acute illness. Although mechanical ventilation is necessary to sustain life in such situations, it can induce weakness of the respiratory muscles which may lead to prolonged dependence on the ventilator. Prolonged dependence on mechanical ventilation is associated with increased mortality, morbidity and costs to the healthcare system. Thus, a main goal of assisted mechanical ventilation is to reduce the patient's respiratory distress while maintaining some respiratory muscle activity. To attain this goal, the amount of ventilator assistance should theoretically be adjusted to target normal or reasonable levels of respiratory effort.
Modes of Mechanical Ventilation:
Proportional assist ventilation with load-adjustable gain factors (PAV+) is a mode of mechanical ventilation which delivers assistance to breathe in proportion to the patient's effort. The proportional assistance, called the gain, can be adjusted by the clinician to maintain the patient's respiratory effort or workload within a reasonable range. This is the only mode of ventilation which allows for measurement and targeting of a specific range of respiratory muscle activity by the patient.
Pressure support ventilation (PSV) is a mode of ventilation which is considered the current standard of care for assisting breathing of patients during the recovery phase of acute respiratory failure. Several studies have shown short term advantages of PAV over PSV, including improved patient-ventilator synchronization, improved adaptability to changes in patient effort, and improved sleep quality.
Goal of this Randomized Controlled Trial:
To demonstrate that for patients with acute respiratory failure, ventilation with PAV+, being more physiological, will result in a shorter duration of time spent on mechanical ventilation than ventilation with PSV.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| PSV ventilation strategy | Active comparator | Other: PSV ventilation strategyThe control is the standard of care PSV ventilation strategy, designed to adjust the level of support according to usual clinical parameters. |
| PAV+ ventilation strategy | Active comparator | Other: PAV+ ventilation strategyThe intervention is a PAV+ ventilation strategy, designed to adjust the level of support (gain) to target a predefined range of respiratory muscle pressure. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PSV ventilation strategyAn algorithm for adjusting the level of pressure support according to usual clinical parameters; patients not tolerating PSV will be switched to Assist/Control mode according to predefined criteria | Other | PSV ventilation strategy |
| PAV+ ventilation strategyAn algorithm for adjusting the level of support (gain) to maintain a predefined range of respiratory muscle pressure; patients not tolerating PAV+ (Puritan Bennett™ 840 or 980 ventilator) will be switched to Assist/Control mode according to predefined criteria | Other | PAV+ ventilation strategy |
Primary outcome
Time from randomization to successful liberation from invasive mechanical ventilation.
Time frame: up to 90 days
"Successful liberation" is defined as removal of the endotracheal tube AND remaining alive with no need for reintubation/reinstitution of invasive mechanical ventilation for 7 days post extubation, or until successful ICU discharge, or until live hospital discharge, whichever comes first.
9 secondary outcomes
Ventilator-free days at 14, 21 and 28 days post randomization
Time frame: 14, 21 and 28 days post randomization
Time from randomization to live ICU discharge (up to day 90)
Time frame: up to 90 days
Time from randomization to live hospital discharge (up to day 90)
Time frame: up to 90 days
Mortality
Time frame: up to 90 days
Weaning Progress
Time frame: up to 90 days
Weaning Difficulties
Time frame: 90 days
Weaning Complications
Time frame: 90 days
Tolerance of modes
Time frame: 90 days
Serious Adverse Events
Time frame: 90 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2025.
- Derived from this study: PubMed 40513024Bosma KJ, Burns KEA, Martin CM, Skrobik Y, Mancebo Cortes J, Mulligan S, Lafreniere-Roula M, Thorpe KE, Suarez Montero JC, Moran Chorro I, Rodriguez-Farre N, Butler R, Bentall T, Beduneau G, Enguerrand P, Santos M, Piraino T, Spadaro S, Montanaro F, Basmaji J, Campbell E, Mercat A, Beloncle FM, Carteaux G, Maraffi T, Charbonney E, Lecronier M, Dres M, Arabi YM, Amaral ACK, Marinoff N, Adhikari NKJ, Geagea A, Shin P, Vaporidi K, Kondili E, Shahin J, Campisi J, Rodriguez PO, Setten M, Goligher EC, Ferguson ND, Fanelli V, Ferreyra G, Lellouche F, Sibley S, Brochard L; PROMIZING Study Investigators, the Canadian Critical Care Trials Group, and the REVA Network. Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation. N Engl J Med. 2025 Sep 18;393(11):1088-1103. doi: 10.1056/NEJMoa2505708. Epub 2025 Jun 13.
- Derived from this study: PubMed 39736673Bosma KJ, Lafreniere-Roula M, Jiang A, Heath A, Ouyang Y, Wade K, Hu P, Burns KEA, Martin CM, Skrobik Y, Mulligan S, Thorpe KE, Brochard L; members of the Canadian Critical Care Trials Group and the REVA Network. Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation (the PROMIZING study): update to the statistical analysis plan for a randomized controlled trial. Trials. 2024 Dec 30;25(1):855. doi: 10.1186/s13063-024-08669-7.
- Derived from this study: PubMed 36973743Bosma KJ, Martin CM, Burns KEA, Mancebo Cortes J, Suarez Montero JC, Skrobik Y, Thorpe KE, Amaral ACK, Arabi Y, Basmaji J, Beduneau G, Beloncle F, Carteaux G, Charbonney E, Demoule A, Dres M, Fanelli V, Geagea A, Goligher E, Lellouche F, Maraffi T, Mercat A, Rodriguez PO, Shahin J, Sibley S, Spadaro S, Vaporidi K, Wilcox ME, Brochard L; Canadian Critical Care Trials Group and; REVA Network. Study protocol for a randomized controlled trial of Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: the PROMIZING study. Trials. 2023 Mar 27;24(1):232. doi: 10.1186/s13063-023-07163-w.
- Published ProtocolLink provided by the sponsor.
- The PROMIZING trial enrollment algorithm for early identification of patients ready for unassisted breathingLink provided by the sponsor.
- PROMIZING WebsiteLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Data will be collected electronically and stored at the Clinical Coordinating Center at the Applied Health Research Centre (AHRC). A de-identified database of all data may be made available for use 3 years after the primary publication upon request and review of the statistical analysis plan by the PROMIZING steering committee.
Related trials for Critically Ill
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
Recruiting
Development and Preliminary Validation of Intelligent Video Laryngoscope for Emergency Use
Critically Ill Patients Requiring Mechanical Ventilation
Active, not recruiting
Weighted Blankets for Agitation in Adults in the Intensive Care Unit
Psychomotor Agitation, Critical Illness
Not yet recruitingObservational study
Core Competencies in General Intensive Care Ultrasound (GenIUS): a Delphi Study
Critical Illness, Ultrasound
RecruitingObservational study
Predicting Extubation Failure Using Machine Learning
Extubation Failure, Critical Illness
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Karen J Bosma principal investigator
London Health Sciences Centre, London, Ontario, Canada
Laurent Brochard principal investigator
St. Michael's Hospital, Toronto, Ontario, Canada
22 sites in 7 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing PSV ventilation strategy and PAV+ ventilation strategy in people with Critically Ill and Acute Respiratory Failure, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's at 22 sites in 7 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 22 sites in Canada, France, Italy, Argentina, Greece and 2 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time from randomization to successful liberation from invasive mechanical ventilation. (time frame: up to 90 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02447692, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2025.